Episode Details

Back to Episodes

“Sobering” Takeaway From ASCO 2026: Concerns About Clinical Trial Participation

Episode 34 Published 1 month, 3 weeks ago
Description

Amid the exciting advances at ASCO 2026, there came a “sobering moment” regarding the U.S.’s role as a cancer clinical trial leader, says Robert A. Winn, MD. He discusses what this means for cancer centers going forward with Robert A. Figlin, MD.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us